Prestige BioPharma Limited (950210.KS)

KRW 15050.0

(-4.57%)

Long Term Debt Summary of Prestige BioPharma Limited

  • Prestige BioPharma Limited's latest annual long term debt in 2023 was 40.87 Billion KRW , down -20.66% from previous year.
  • Prestige BioPharma Limited's latest quarterly long term debt in 2023 Q3 was 42.57 Billion KRW , down -4.98% from previous quarter.
  • Prestige BioPharma Limited reported annual long term debt of 51.51 Billion KRW in 2022, up 1839.71% from previous year.
  • Prestige BioPharma Limited reported annual long term debt of 2.65 Billion KRW in 2021, down -25.63% from previous year.
  • Prestige BioPharma Limited reported quarterly long term debt of 48.97 Billion KRW for 2023 Q1, down -4.94% from previous quarter.
  • Prestige BioPharma Limited reported quarterly long term debt of 42.57 Billion KRW for 2023 Q3, down -4.98% from previous quarter.

Annual Long Term Debt Chart of Prestige BioPharma Limited (2023 - 2017)

Historical Annual Long Term Debt of Prestige BioPharma Limited (2023 - 2017)

Year Long Term Debt Long Term Debt Growth
2023 40.87 Billion KRW -20.66%
2022 51.51 Billion KRW 1839.71%
2021 2.65 Billion KRW -25.63%
2020 3.57 Billion KRW 46.69%
2019 2.43 Billion KRW 4959.67%
2018 48.11 Million KRW 24.5%
2017 38.64 Million KRW 0.0%

Peer Long Term Debt Comparison of Prestige BioPharma Limited

Name Long Term Debt Long Term Debt Difference
ORIENT BIO Inc. 2.43 Billion KRW -1577.419%
Green Cross Holdings Corporation 216.35 Billion KRW 81.109%
Green Cross Holdings Corporation 84.89 Billion KRW 51.854%
Pharmicell Co., Ltd. 390.21 Million KRW -10373.963%
Green Cross Corporation 84.89 Billion KRW 51.854%
GeneOne Life Science, Inc. 6.27 Billion KRW -551.566%
Celltrion, Inc. 99.13 Billion KRW 58.771%
Samsung Biologics Co.,Ltd. 377.39 Billion KRW 89.17%
SK bioscience Co.,Ltd. 12.43 Billion KRW -228.651%
SK Biopharmaceuticals Co., Ltd. 94.48 Billion KRW 56.743%